1 / 13

Outcome Measures in PsA

Outcome Measures in PsA. Philip Mease MD Seattle, WA. Measures of PsA Outcome. ACR Response Criteria: 20%, 50%, 70% (validated in RA, not PsA) Tender and swollen joint count (modified for PsA to include DIP and CMC joints: 78/76)

cain-petersen
Télécharger la présentation

Outcome Measures in PsA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Outcome Measures in PsA Philip Mease MD Seattle, WA

  2. Measures of PsA Outcome • ACR Response Criteria: 20%, 50%, 70% (validated in RA, not PsA) • Tender and swollen joint count (modified for PsA to include DIP and CMC joints: 78/76) • 3/5: patient global, physician global, patient pain, HAQ, acute phase reactant (sed rate, CRP) • Psoriatic Arthritis Response Criteria (PsARC)* • Improvement in at least 2 of 4 criteria, including: • Physician global assessment (0-5) • Patient global assessment (0-5) • Tender joint score (>30%) • Swollen joint score (>30%) • Improvement in at least 1 of 2 joint scores • No worsening in any criteria • Disease Activity Score (DAS) * Clegg DO. Arthritis Rheum. 1996;39:2013.

  3. Measures of PsA Outcome (cont.) • Enthesitis score • Dactylitis score • Function/QOL/Disability Indices (HAQ, SF-36, DLQI, PsAQOL) • Radiographic (Modified Sharp, Modified Steinbrocker, Wassenberg) (to be discussed by van der Heijde) • Skin (PASI, target lesion, static global) (to be discussed by G Krueger)

  4. Prior RCTs in PsA *Psoriasis Area and Skin Index. ** Number of controlled studies

  5. Bibliography of Key RCTs in PSA • Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum 2002;46(9):S381. • Antoni C, Kavanaugh A, Kirkham B, Burmester G, et al. The One Year Results of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Substantial Efficacy on Synovitis and Psoriatic Lesions With or Without Concomitant DMARD Therapy. Arthritis Rheum 2003;48(9):S265. • Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39(12):2013-20. • Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthrits and psoriasis. Arthritis Rheum 2004;50(6):1939-50. • Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385-90. • Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;(in press July).

  6. Pure PsA vs. Mixed SpA Trials • Valuable data about PsA response to therapy discernable from mixed SpA trials • Uncertainty about the validity of instruments such as the BASDAI in PsA if there is little or no spine involvement

  7. Unique Elements of PsA Trials • Inclusion of oligoarticular patients • Allowance of other DMARD background in trials with biologics • Equal gender prevalence • Assessment of skin

  8. Therapeutic Responses in PsA Effect on Joint Disease * 12 weeks; ** 16 weeks;***24 weeks

  9. Mean Values >5.1 Non-responders <3.2 Good Response Mean DAS 28 Score 0 18 2 10 16 38 14 30 50 6 22 46 Week DAS28 Score Over Time

  10. Enthesitis Over Time (IMPACT I) Number of Patients with Enthesitis *p=0.05 vs placebo

  11. Dactylitis Score (IMPACT I) Dactylitis Score

  12. Therapeutic Responses in PsA: HAQ Changes p value • Etanercept II 1.20 <.0001 • Etanercept III .54 <.0001 • Infliximab II .60 <.0001 • Leflunomide .19 .0267

  13. Domain Joint assessment Axial assessment* Skin assessment Pain Patient global Physician global Function/QOL* Fatigue* Enthesial assessment* Dactylitis assessment* Stiffness Acute phase reactants Xray* MRI* Ultrasound* Clinical subset response* *Needs development/validation Instrument T/S joint count, ACR, PsARC, DAS* ? PASI, Target lesion, Global VAS VAS VAS HAQ, SF-36, DLQI, PsAQOL Krupp, MFI, FACIT, one question Mander, MASES, present or absent 0-4 scale, Helliwell scale Duration minutes ESR, CRP Sharp, Larsen, Steinbrocker ? ? Need clear guidelines to define clinical subsets in order to assess subset response Core Sets in PsA

More Related